Top Abstract Purchase Related
Home
>
Node
>
Subnode

Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer

Magnusson, C.; Weiderpass, E.

Lakartidningen 98(5): 418-421

2001

ISSN/ISBN: 0023-7205
PMID: 11229082
Document Number: 534632
Use of hormone replacement therapy alleviates menopausal symptoms effectively, prevents osteoporosis and may even reduce the risk of cardiovascular disease and dementia. However, little is known about the risk of breast cancer and endometrial cancer after long-term use of different estrogen-progestin combinations. A large epidemiological study in Sweden, in which combined estrogen-progestin treatment was predominantly used, is reported.

Document emailed within 1 workday
Secure & encrypted payments

2002: New SBU-report on estrogen replacement therapy in climacteric. Moderate risk of breast cancer after long-term use Lakartidningen 99(28-29): 3031-3034
Santen, R.J.; Pinkerton, J.; McCartney, C.; Petroni, G.R. 2001: Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy Journal of Clinical Endocrinology and Metabolism 86(1): 16-23
Dryzhak, V.I. 1989: Estrogen antagonists and inhibitors in hormone therapy of breast cancer Voprosy Onkologii 35(7): 771-778
Tavani, A.; La Vecchia, C.; Brinton, L.A.; McTiernan, A. 2001: Hormone replacement therapy and risk of endometrial cancer Tumori 87(5): S20-S21
Berndt, G.; Eckel, H.; Notter, G.; St Stender, H. 1971: Effect of estrogen-gestagen combination therapy in advanced breast carcinoma with special reference to pulmonary metastases Strahlentherapie 141(5): 540-548
Grant, E.C.G. 2017: Lifetime cancer risk with progestin and estrogen oral contraceptives and hormone therapy American Journal of Obstetrics and Gynecology 217(2): 232-233
Ciatto, S.; Pacini, P.; Confortini, M.; Massimo, V. 1994: Reliability of immunocytochemical assay of estrogen receptors on breast cancer aspirates as a predictor of clinical response to hormone therapy Acta Cytologica 38(4): 666-667
Kalogirou, D.; Antoniou, G.; Karakitsos, P.; Kalogirou, O.; Antoniou, D.; Giannikos, L. 1996: A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response International Journal of Fertility and Menopausal Studies 41(6): 522-527
Chen, F.-P. 2009: Postmenopausal hormone therapy and risk of breast cancer Chang Gung Medical Journal 32(2): 140-147
Rotkina, I.E. 1973: Adrenal hormone content in the plasma and urine during treatment with estrogen-gestagen preparations Akusherstvo i Ginekologiia 49(8): 63-66
Pinkerton, J.V.; Wilson, C.S.; Kaunitz, A.M. 2022: Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer Menopause 29(9): 1001-1004
Persson, I. 1984: Estrogen treatment and the risk of endometrial cancer Lakartidningen 81(20): 2068-2071
Ratanawichitrasin, A.; Reansuwan, W.; Ratanawichitrasin, S.; Bhodhisuwan, K.; Kongpatanakul, S. 2002: Risk of breast cancer in post-menopausal women using hormone replacement therapy Journal of the Medical Association of Thailand 85(5): 583-589
Ruan, X.; Seeger, H.; Mueck, A.O. 2012: Breast cancer risk during hormone therapy: experimental versus clinical data Minerva Endocrinologica 37(1): 59-74
Zylberberg, B.; Dormont, D. 1996: Biweekly menopausal substitutive hormone therapy: effects on climacteric and prevention of osteoporosis Contraception Fertilite Sexualite 24(12): 874-878
Eliassen, A.H.; Hankinson, S.E. 2008: Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies Advances in Experimental Medicine and Biology 630: 148-165
Uhlenbruck, G.; VAN Leendert, R.; Schneider, B.; Beuth, J. 2010: Reduced side-effects of adjuvant hormone therapy in breast cancer patients by complementary medicine In Vivo 24(5): 799-802
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Cook, L.S.; Dong, Y.; Round, P.; Huang, X.; Magliocco, A.M.; Friedenreich, C.M. 2014: Hormone contraception before the first birth and endometrial cancer risk Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 23(2): 356-361
Nomura, Y.; Tashiro, H.; Hisamatsu, K.; Toi, M. 1988: Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 513-518